Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hypertension

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 25 articles: HTML format

Single Articles

July 2025
1. PEREIRA DA SILVA AM, da Silva Torres E, da Vitoria Santos do Nascimento M, Franco JO, et al
   Genetic and Epigenetic Biomarkers in Hypertension: Impact on the Effectiveness of Individualized Therapy: A Systematic Review.
   J Cardiovasc Pharmacol. 2025 Jul 28. doi: 10.1097/FJC.0000000000001743.
   PubMed     Abstract available
   
   
   
2. BAL NB, Sadi G, Bostanci A, Kiremitci S, et al
   Effect of regular exercise and resveratrol on hypertension-induced cellular stress response and senescence in renal and vascular tissues of rats.
   J Cardiovasc Pharmacol. 2025 Jul 24. doi: 10.1097/FJC.0000000000001744.
   PubMed     Abstract available
   
   
   
3. ZHU M, Xu F, Zhu L, Chen Q, et al
   FAP Promotes Pulmonary Artery Hypertension via Activation of the PTEN/PI3K/Akt Pathway.
   J Cardiovasc Pharmacol. 2025 Jul 17. doi: 10.1097/FJC.0000000000001735.
   PubMed     Abstract available
   
   
   May 2025
4. LIU P, Meng Z, Zhang L, Li G, et al
   Effect of HDAC4 regulation of beta-catenin signaling pathway on cardiac injury in spontaneously hypertensive rats and its mechanism.
   J Cardiovasc Pharmacol. 2025 May 29. doi: 10.1097/FJC.0000000000001724.
   PubMed     Abstract available
   
   
   April 2025
5. PEDDI AN, Wheeler SE, Akkisetty K, Bucheit JD, et al
   Aprocitentan for Treatment-Resistant Hypertension: Pharmacology Concepts and Clinical Insights.
   J Cardiovasc Pharmacol. 2025 Apr 11. doi: 10.1097/FJC.0000000000001700.
   PubMed     Abstract available
   
   
   February 2025
6. EID AH
   A Game Changer for Resistant Hypertension: The Rise of Aprocitentan.
   J Cardiovasc Pharmacol. 2025 Feb 4. doi: 10.1097/FJC.0000000000001679.
   PubMed     Abstract available
   
   
   
7. WANG S, Zhuo D, Lin J, Zhang C, et al
   Key Genes and Biological Pathways in Pulmonary Arterial Hypertension Related to Endoplasmic Reticulum Stress Identified by Bioinformatics.
   J Cardiovasc Pharmacol. 2025;85:108-119.
   PubMed     Abstract available
   
   
   January 2025
8. ANTO S, Sun C, O'Rourke ST
   Activation of APJ Receptors by CMF-019, But Not Apelin, Causes Endothelium-Dependent Relaxation of Spontaneously Hypertensive Rat Coronary Arteries.
   J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001671.
   PubMed     Abstract available
   
   
   
9. CHEN X, Xu L, Xue B
   Efficacy and safety of Treating Pulmonary Arterial Hypertension With Imatinib:A meta-analysis of randomized controlled trials.
   J Cardiovasc Pharmacol. 2025 Jan 2. doi: 10.1097/FJC.0000000000001665.
   PubMed     Abstract available
   
   
   November 2024
10. FIRMINO FT, Peixoto P, Batista TJ, da Silva Escouto L, et al
    High dose of liraglutide impairs renal function in female hypertensive rats.
    J Cardiovasc Pharmacol. 2024 Nov 8. doi: 10.1097/FJC.0000000000001649.
    PubMed     Abstract available
    
    
    August 2024
11. LIANG YF, You QX, Chen SY, Ni L, et al
    The Impact of Hydrogen Sulfide in the Paraventricular Nucleus on the MAPK Pathway in High Salt-Induced Hypertension.
    J Cardiovasc Pharmacol. 2024 Aug 8. doi: 10.1097/FJC.0000000000001622.
    PubMed     Abstract available
    
    
    July 2024
12. DENG J, Yang G, Zhong N, Liang L, et al
    Upregulation of Angiomotin-like 2 ameliorates experimental pulmonary arterial hypertension by inactivating YAP1 signaling.
    J Cardiovasc Pharmacol. 2024 Jul 2. doi: 10.1097/FJC.0000000000001606.
    PubMed     Abstract available
    
    
    June 2024
13. ZHANG XL, Li JP, Wu MZ, Wu JK, et al
    Quercetin protects against hypertensive renal injury by attenuating apoptosis: an integrated approach using network pharmacology and RNA-Seq.
    J Cardiovasc Pharmacol. 2024 Jun 4. doi: 10.1097/FJC.0000000000001598.
    PubMed     Abstract available
    
    
    May 2024
14. LUZ DE CASTRO A, Ortiz VD, Hickmann AR, Lacerda DS, et al
    EFFECTS OF PTEROSTILBENE ON HEART AND LUNG OXIDATIVE STRESS PARAMETERS IN TWO EXPERIMENTAL MODELS OF CARDIOVASCULAR DISEASE: MYOCARDIAL INFARCTION AND PULMONARY ARTERIAL HYPERTENSION.
    J Cardiovasc Pharmacol. 2024 May 4. doi: 10.1097/FJC.0000000000001572.
    PubMed     Abstract available
    
    
    
15. SHU Z, Feng J, Liu L, Liao Y, et al
    Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis.
    J Cardiovasc Pharmacol. 2024;83:410-432.
    PubMed     Abstract available
    
    
    
16. PONTES CNR, Bessa ASM, Macedo LM, Ferreira-Junior MD, et al
    Angiotensin-(1-7) Treatment Early in Life Prevents Cardiac Hypertrophy in Adult Hypertensive Rats.
    J Cardiovasc Pharmacol. 2024;83:457-465.
    PubMed     Abstract available
    
    
    March 2024
17. CONZATTI A, Colombo R, Siqueira R, Campos-Carraro C, et al
    Sulforaphane improves redox homeostasis and right ventricular contractility in a model of pulmonary hypertension.
    J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001557.
    PubMed     Abstract available
    
    
    
18. RIBEIRO PONTES CN, de Sa Martins de Bessa A, Macedo LM, Ferreira-Junior MD, et al
    ANGIOTENSIN-(1-7) TREATMENT EARLY IN LIFE PREVENTS CARDIAC HYPERTROPHY IN ADULT HYPERTENSIVE RATS.
    J Cardiovasc Pharmacol. 2024 Mar 12. doi: 10.1097/FJC.0000000000001530.
    PubMed     Abstract available
    
    
    February 2024
19. JIANG K, Jia Y, Chen L, Huang F, et al
    Association of IL-17 Inhibitors with Hypertension in Patients with Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2024 Feb 27. doi: 10.1097/FJC.0000000000001547.
    PubMed     Abstract available
    
    
    January 2024
20. KUMARI K, Vishwakarma VK, Kumar K, Mridha AR, et al
    Effect of benidipine alone and in combination with bosentan and sildenafil in amelioration of pulmonary arterial hypertension in experimental model in rats.
    J Cardiovasc Pharmacol. 2024 Jan 17. doi: 10.1097/FJC.0000000000001541.
    PubMed     Abstract available
    
    
    
21. LI J, He X, Liu F, Zheng X, et al
    Tumor Necrosis Factor-alpha-Induced Protein-8-like 2 Transfected Adipose-Derived Stem Cells Regulated the Dysfunction of Monocrotaline Pyrrole-Induced Pulmonary Arterial Smooth Muscle Cells and Pulmonary Arterial Endothelial Cells.
    J Cardiovasc Pharmacol. 2024;83:73-85.
    PubMed     Abstract available
    
    
    December 2023
22. ATEFIPOUR N, Dianat M, Badavi M, Radan M, et al
    The Role of Rosmarinic Acid in the Protection against Inflammatory Factors in Rats Model with Monocrotaline-Induced Pulmonary Hypertension: Investigating the Signaling Pathway of NFkappaB, OPG, Runx2, and P-selectin in Heart.
    J Cardiovasc Pharmacol. 2023 Dec 26. doi: 10.1097/FJC.0000000000001534.
    PubMed     Abstract available
    
    
    November 2023
23. KELLY MS, Dacey A, Siana A, Ojeda J, et al
    Efficacy and Safety of a polypill to reduce cardiovascular events: A review of clinical trials.
    J Cardiovasc Pharmacol. 2023 Nov 4. doi: 10.1097/FJC.0000000000001508.
    PubMed     Abstract available
    
    
    September 2023
24. LIU R, Staruschenko A
    Matrix Metalloproteinase 2 is crucial for hypertension- and hyperglycemia-induced kidney injury independent of blood pressure.
    J Cardiovasc Pharmacol. 2023 Sep 28. doi: 10.1097/FJC.0000000000001488.
    PubMed    
    
    
    August 2023
25. KAPLAN A, Lakkis B, El-Samadi L, Karaayvaz EB, et al
    Cooling Down Inflammation in the Cardiovascular System via the Nicotinic Acetylcholine Receptor.
    J Cardiovasc Pharmacol. 2023 Aug 4. doi: 10.1097/FJC.0000000000001455.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.